A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

17/02/2017
14/03/2024
EU PAS number:
EUPAS17875
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

GS-US-334-1113-appendix-16.1.1-protocol_f-redact

English (876.81 KB - PDF) View document
Updated protocol

GS-US-334-1113-appendix-16.1.1-protocol Amendment 3_f-redact

First published: 22/02/2024
English (829.86 KB - PDF) View document
Study results
Study results

GS-US-334-1113-CSR-synopsis_f-redact

English (724.29 KB - PDF) View document
Study report
Other information